Abstract
Introduction
Ischaemic stroke is the leading global cause of disability in the developed world, and the third leading cause of mortality [1] . Due to an increasing live expectancy, the rate of first stroke is still expected to rise despite of increasingly effective prevention strategies. About 75-85% of patients survive a first ischaemic stroke, but between 8% and 15% suffer a recurrent stroke in the first year. Risk of stroke recurrence or stroke following transient ischaemic attack (TIA) is highest in the first days following the cerebrovascular event and declines over time [2, 3] . Antithrombotic In this review, we will discuss current best evidence of antiplatelet therapy in acute and long-term secondary stroke prevention. [39] [40] . [41] [43] and dipyridamole might also induce migraine attacks in patients with a known migraine without aura [44] . There are several reports about a mechanism of action of dipyridamole on the vascular system. Dipyridamole inhibits the reuptake of adenosine by red blood cells, platelets and the vascular endothelium, thereby increasing the extracellular level of adenosine [45] . Adenosine [56] .
Aspirin plus dipyridamole

The combination of low-dose aspirin and dipyridamole was first investigated in the randomized Second European stroke prevention (ESPS) 2 study with 6602 included patients with a TIA or ischaemic stroke [37]. Patients were randomized to receive aspirin alone (25 mg/twice a day), extended release dipyridamole (200 mg/twice a day), the combination of aspirin and extended release dipyridamole or placebo. For the primary end-point stroke, the combination therapy was superior to aspirin monotherapy (relative risk reduction 23%, absolute risk reduction 3%/2 years) and to placebo (relative risk reduction 37%, absolute risk reduction 5.8%/2 years). Aspirin monotherapy lowered the risk of stroke by 18% (absolute risk reduction 2.9%/2 years) and dipyridamole monotherapy by 16% (absolute risk reduction 2.6%/2 years) compared to placebo. Major bleeding complications were seen more frequently with aspirin and the combination aspirin and dipyridamole, whereas dipyridamole monotherapy had a similar bleeding rate compared with placebo. Cardiac events occurred in similar frequency in the groups treated with dipyridamole compared to aspirin [38]. The results of the ESPS-2 study could be replicated by the investigator-initiated ESPRIT trial
Aspirin plus dipyridamole versus clopidogrel
A direct head-to-head comparison of the combination aspirin (25 mg/twice a day) and extended-release dipyridamole (200 mg/twice a day) with clopidogrel (75 mg/day) did not show any significant difference in efficacy across major end-points in the PRoFESS (prevention regimen for effectively avoiding second strokes) trial
Antiplatelets in patients with symptomatic intracranial stenosis
The WASID (warfarin-aspirin symptomatic intracranial disease) trial compared oral anticoagulation with warfarin (target INR 
